EMA CHMP recommends approval of Opdivo + chemo for the neoadjuvant treatment of PD-L1 positive, resectable NSCLC at a high risk of recurrence

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Three years ago, researchers from Memorial Sloan Kettering Cancer Center published stunning results: For the 5% of rectal cancer patients whose tumors are mismatch-repair deficient, neoadjuvant dostarlimab-gxly (Jemperli) has the makings of a silver bullet.

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

When Kelly Spill was eight months pregnant, she experienced some constipation and noticed blood in her stool. Her OBGYN wasn’t worried.

CHMP adopts positive opinion for Adcetris + ECADD for newly diagnosed stage IIb/III/IV Hodgkin lymphoma

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the extension of the marketing authorization of Adcetris (brentuximab vedotin) and recommended its approval in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone, a chemotherapy regimen, in adult patients with newly diagnosed stage 2b with risk factors/3/4 Hodgkin lymphoma.

May 02, 2025

Vol.51 No.17

Drugs & Targets

CHMP adopts positive opinion on Calquence-based regimens for CLL

The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended a fixed-duration regimen of Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab for approval in the EU for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.

May 02, 2025

Vol.51 No.17

Clinical

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Immunotherapy has changed the course of blood cancers and melanomas, but is stubbornly ineffective for the treatment of most epithelial solid cancers—the cancers that kill about 90% of the more than 600,000 Americans who die of cancer each year.

April 18, 2025

Vol.51 No.15

By Jacquelyn Cobb

Conversation with The Cancer Letter

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.

April 04, 2025

Vol.51 No.13

By Paul Goldberg

EMA CHMP recommends approval of Opdivo + chemo for the neoadjuvant treatment of PD-L1 positive, resectable NSCLC at a high risk of recurrence

YOU MAY BE INTERESTED IN

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

CHMP adopts positive opinion for Adcetris + ECADD for newly diagnosed stage IIb/III/IV Hodgkin lymphoma

CHMP adopts positive opinion on Calquence-based regimens for CLL

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Renew today!

Subscriber content

Never miss an issue!

Login

EMA CHMP recommends approval of Opdivo + chemo for the neoadjuvant treatment of PD-L1 positive, resectable NSCLC at a high risk of recurrence

YOU MAY BE INTERESTED IN

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertileSix years later, she is well—and pregnant with her third child

CHMP adopts positive opinion for Adcetris + ECADD for newly diagnosed stage IIb/III/IV Hodgkin lymphoma

CHMP adopts positive opinion on Calquence-based regimens for CLL

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Never miss an issue!

Login

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child